Barclays has downgraded three European consumer ingredients stocks and cut earnings forecasts across the sector, warning that a renewed energy-driven inflation shock from the Middle East conflict will push out the volume recovery investors had been counting on in 2026.

The bank cut Givaudan to Equal Weight from Overweight, Barry Callebaut to Underweight from Equal Weight, and Corbion to Equal Weight from Overweight, while trimming price targets across most of its coverage universe.

EBITDA forecasts were cut by 2-7% for 2026, with the sharpest reductions at Givaudan, Symrise, and Barry Callebaut.

Using a base case of $85 per barrel oil and €45/MWh European gas for 2026, Barclays estimates companies will need to push through roughly 3% of incremental pricing in the second half of the year to offset gross profit pressure.

Fragrance-exposed names such as Givaudan and Symrise face the steepest pricing requirements given their higher share of oil-linked raw materials.

The bank raised 2026 pricing assumptions by 1-3% across the group, but cut volume estimates by 1-3%, as customers are expected to prioritise margin protection over innovation — pushing out what was meant to be a long-awaited demand recovery.

“Pricing power should hold, but volume — not cost — is the key concern,” analysts led by Alex Sloane said in a note.

The case against Givaudan is the most acute. The analysts cited the company’s high oil-linked input costs, the largest Middle East exposure in the group — where Fine Fragrance has been a major growth engine — and continued underperformance in its Taste & Wellbeing division.

“We see risk of a Q2 air pocket as disruption in the Middle East hits orders with a lag,” the team wrote, while Givaudan’s valuation still carries a premium to peers that, in Barclays’ view, looks increasingly difficult to defend.

The price target was lowered to 3,050 from CHF 3,550 Swiss francs.

Barry Callebaut was downgraded on the grounds that its sharp re-rating over the past year — shares have nearly doubled from their lows — leaves little room for error.

The analysts flagged that every £100 per tonne move in cocoa drives 70-80 million Swiss francs of working-capital impact, and that the new CEO’s mandate to restore competitiveness raises the probability of reinvestment that would cap EBIT recovery.

“This would be sensible for the long-term health of the business but we think does leave risk of downgrades near term,” the analysts said.

Corbion was also downgraded as its volume-dependent outlook looks increasingly stretched. The bull case hinges on a step-up in Food Ingredients & Solutions volumes, but with customers again prioritising margin protection over innovation, analysts said this looks unlikely to materialise in 2026.

In this backdrop, Barclays said Novonesis remains its preferred name, retaining an Overweight rating. “We continue to prefer Novonesis, where structural demand in dairy/protein, enzyme solutions that help reduce customer costs, and strongest pricing power provide relative resilience in a more inflationary world,” the analysts said.